Manifesto 2024 - endorsements
In the EU, cancer deaths are expected to increase by more than 24% by 2035 and this will make cancer the leading cause of death. The overall economic impact of cancer is estimated to exceed €100 billion annually.
European decision-makers aim to bring the best possible treatments to every patient. However, if we desire a future where cancer is no longer a life-threatening disease, all potentially impactful cancer research must be given equal attention.
Our Manifesto 2024-2029 outlines specific actions that can transform cancer treatment. We ask policy makers to address them within the next five years.
Endorse the Manifesto. By doing so, you declare your awareness and willingness to support the access to more and better treatments for all cancer patients.
Organisations that endorse our manifesto to this date
AIM Healthcare and Social Benefits for All
Acute Leukemia Advocates Network
Fondation ARC pour la recherche sur le cancer
Asociación Española Contra el Cáncer
Barncancer Fonden
Breast International Group
Cancer Patients Europe
Childhood Cancer International
Cures within Reach
Cutaneous Lymphoma Foundation
Digestive Cancers Europe
European Association for Clinical Pharmacology and Therapeutics
European Academy of Cancer Sciences
Association of European Cancer Leagues
European Fair Pricing Network
Morningside Center for Innovative and Affordable Medicine
European Organisation for Research and Treatment of Cancer
European Cancer Organisation
Eurordis
Centre for Future Affordable Sustainable Therapy Development
Fondazione Paola Gonzato Rete Sarcoma ETS
Global Cures
Institute of Cancer Policy
International Brain Tumour Alliance
Istitute di Ricerche Farmalogiche Mario Negri
Kom op tegen Kanker
Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding
Oncode Institute
Pancreatic Cancer Europe
Rising Tide Foundation for Clinical Cancer Research
Sarcoma Patient Advocacy Global Network
the European Society for Paediatric Oncology
Solving Kid's Cancer
UZ Brussel
Workgroup of European Cancer patient Advocacy Networks